Overview

Customized Neoadjuvant Versus Standard Chemotherapy in NSCL Patients With Resectable Stage IIIA (N2)Disease

Status:
Unknown status
Trial end date:
2015-12-01
Target enrollment:
Participant gender:
Summary
- The investigators hypothesized that NSCL patients receiving therapy based on their baseline tumor markers levels would attain higher response rates than patients in the control arm receiving non customized therapy. - patients with stage IIIA(N2) NSCLC will be randomized in a 2:1 ratio to customized therapy based on biomarkers status (ERCC1, RRM1, TS and EGFR mutation) vs standard chemotherapy. - The primary objective of this multicenter trial is to compare pathological complete response of all subjects randomized, by treatment arm. - Secondary objectives are to compare all randomized subjects by treatment arm for: response rate, disease-free survival, overall survival, one, two and three year survival and safety profile. The study is expected to demonstrate both the feasibility of this approach and the logistic problems associated with a biomarker-driven therapeutic strategy in NSCLC.
Phase:
Phase 2
Details
Lead Sponsor:
IRCCS Azienda Ospedaliera Universitaria San Martino - IST Istituto Nazionale per la Ricerca sul Cancro, Genoa, Italy
Collaborators:
ASL TO4, Chivasso
Azienda Ospedaliera "Sant'Andrea"
Azienda Ospedaliera dei Colli
Azienda Ospedaliera dei Colli Monaldi-Cotugno-CTO, Napoli
Azienda Ospedaliera S. Maria della Misericordia
Azienda Ospedaliera San Camillo Forlanini
Azienda Ospedaliera San Gerardo di Monza
Azienda Ospedaliera San Giovanni Battista
Azienda Ospedaliera Sant'Andrea, Roma
Azienda Ospedaliera Santa Maria Degli Angeli
Azienda Ospedaliera Spedali Riuniti di Livorno, Livorno
Azienda Ospedaliera Universitaria Integrata Verona
Azienda Ospedaliera, Ospedale Civile di Legnano
Azienda Provinciale per i Servizi Sanitari, Provincia Autonoma di Trento
Azienda Sanitaria Locale di Cagliari
Azienda Sanitaria Locale n.2 Savonese
Istituto Clinico Humanitas
Istituto Tumori Giovanni Paolo II, BARI
Ospedale Santa Croce-Carle Cuneo
Treatments:
Cisplatin
Docetaxel
Gefitinib
Gemcitabine
Pemetrexed
Vinblastine
Vinorelbine